References
- Nguyen NC, Kaushik A, Wolverson MK, Osman MM. Is there a common SUV threshold in oncological FDG PET/CT, at least for some common indications? A retrospective study. Acta Oncol 2011 doi: 10.3109/0284186X.2010.550933.
- Basu S, Zhuang H, Torigian DA, Rosenbaum J, Chen W, Alavi A. Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med 2009;39: 124–45.
- Basu S, Chryssikos T, Moghadam-Kia S, Zhuang H, Torigian DA, Alavi A. Positron emission tomography as a diagnostic tool in infection: Present role and future possibilities. Semin Nucl Med 2009;39:36–51.
- Kim BH, Na MA, Kim IJ, Kim SJ, Kim YK. Risk stratification and prediction of cancer of focal thyroid fluorodeoxyglucose uptake during cancer evaluation. Ann Nucl Med 2010;24:721–8.
- Traugott AL, Dehdashti F, Trinkaus K, Cohen M, Fialkowski E, Quayle F, . Exclusion of malignancy in thyroid nodules with indeterminate fine-needle aspiration cytology after negative 18F-fluorodeoxyglucose positron emission tomography: Interim analysis. World J Surg 2010;34: 1247–53.
- Kim BH, Na MA, Kim IJ, Kim SJ, Kim YK. Risk stratification and prediction of cancer of focal thyroid fluorodeoxyglucose uptake during cancer evaluation. Ann Nucl Med 2010;24:721–8.
- Magini G, Farsad M, Frigerio M, Serra C, Colecchia A, Jovine E, . C-11 acetate does not enhance usefulness of F-18 FDG PET/CT in differentiating between focal nodular hyperplasia and hepatic adenoma. Clin Nucl Med 2009;34: 659–65.
- Patel PM, Alibazoglu H, Ali A, Fordham E, LaMonica G. ‘False-positive’ uptake of FDG in a hepatic adenoma. Clin Nucl Med 1997;22:490–1.